TORONTO, June 17, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that naked veltuzumab enhances the therapeutic response to a veltuzumab-based pretargeted radioimmunotherapy (PT-RAIT) in a human non-Hodgkin's lymphoma model.
